Navigation Links
Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing

SAN DIEGO, May 3, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that several members of management will speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing.  The conference is taking place May 8-11, 2011 at the Toronto Convention Center.  

  • James Levine, President and Chief Executive Officer, will make opening remarks at a plenary breakfast, What Consumers and Manufacturers Need from Industrial Biotech Companies: A Customer Perspective on Tuesday, May 10th at 7:00 am.
  • Janet Roemer, Chief Operating Officer, will be moderating a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, on Wednesday, May 11th at 11:00 am. Roemer will also be speaking on a panel, The Power of Enzymes, Tuesday, May 10th at 3:00 pm
  • Ken Barrett, Vice President, Business Development, will be moderating a panel, Protein Engineering and Screening Methods, Tuesday, May 10th at 9:00 am.
  • David Weiner, Ph.D., Vice President, R&D Strategy and Partnerships, will be speaking on a panel, The Industrial Biotech Revolution, Has it Lived up to the Hype?, Wednesday, May 11th at 11:00 am.

  • The Company will also have a booth at space 316 in the Toronto Convention Center.

    For more information on the BIO Industrial Biotechnology Conference please visit

    About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at

    Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

    Vice President, Corporate Communications


    Sarah Carmody

    Manager, Corporate Communications


    SOURCE Verenium Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
    3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
    4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
    5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    6. Verenium Announces First Commercial Cellulosic Ethanol Project
    7. Verenium Announces Organizational Changes
    8. Verenium Completes Amendment to 8% Senior Convertible Notes
    9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
    10. Verenium Announces Reverse Stock Split to Take Effect September 9
    11. Verenium 1:12 Reverse Stock Split Takes Effect
    Post Your Comments:
    (Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group announced that its scientific ... for isolating adipose-derived stem cells. The announcement starts a new phase toward launching the ... a component of the lipoaspirate obtained from liposuction of excess adipose tissue. , ...
    (Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care hub ... northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. , ... cell medicine to patients from around the world. , The clinics will be headed by ...
    (Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
    (Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, ... assistant chemistry professor Jan Halámek, is taking crime ...   --> ...   --> --> ... UAlbany have discovered a straightforward concept for identifying ...
    Breaking Biology Technology:
    (Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
    (Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
    (Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
    Breaking Biology News(10 mins):